Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.
about
Systemic delivery of oncolytic viruses: hopes and hurdlesOvercoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeOncolytic viruses: finally deliveringDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsThe Cell Adhesion Molecule “CAR” and Sialic Acid on Human Erythrocytes Influence Adenovirus In Vivo BiodistributionTraceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivoMyocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeabilityEnhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasoundPreclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic AdenovirusThe influence of innate and pre-existing immunity on adenovirus therapyOncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanomaActive adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectinsHelper-dependent adenoviral vectors for liver-directed gene therapy.Methods to improve cardiac gene therapy expression.Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivoCircumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous deliveryCurrent advances and future challenges in Adenoviral vector biology and targetingGene therapy targeting to tumor endothelium.Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors.Viral vectors: from virology to transgene expressionOncolytic viruses: a novel form of immunotherapy.Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice.Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood.Helper-Dependent Adenoviral Vectors.Innate immunity to adenovirus.Oncolytic vaccinia virus for the treatment of cancer.Advances and future challenges in adenoviral vector pharmacology and targeting.Oncolytic viruses: do they have a role in anti-cancer therapy?Manipulation of adenovirus interactions with host factors for gene therapy applications.Virotherapy of neuroendocrine tumors.Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Angiogenic gene therapy for refractory angina.Oncolytic virotherapy for head and neck cancer: current research and future developments.Quantum dot labelling of adenovirus allows highly sensitive single cell flow and imaging cytometry.Adenovirus sensing by the immune system.
P2860
Q21284969-EA5E58CB-44C7-4A32-A33D-76F61FD82A0CQ26769977-6C8A913F-030A-406D-9446-ECBC63E78012Q26772039-A265B829-083C-4460-BAC0-9EE827EEEF14Q26782083-A6D8C3D3-8519-464B-8405-79A74F9A0DBDQ27653315-29320753-BD73-4E29-9244-68063BAB2DD5Q28539158-1DB7E7C1-F29D-49B8-89FB-88A90C331696Q30440788-EBAF8120-33D2-4514-9093-F46602A9AFA7Q30446996-3B18D266-E480-48AC-A3D3-6D03DD242AD6Q33633287-39FB0EC2-ADCB-4985-86BB-91651A79E5C7Q33655401-F3DC1D9C-7A59-4B8F-BBC8-B02F26F3FB63Q33906116-04E76AB7-EA6A-4045-94B4-A5E8192B2217Q33931576-2E47E099-8004-4CA9-9E24-1349DEFA63F8Q34473301-6B8A4064-8718-4894-98CB-876682E18662Q34765825-50118D89-083E-4C5A-8AB0-7B2C5AC3D2FEQ34982825-1F15C758-D45B-449A-9F8E-E1017E6EB47CQ35360600-3EDC4035-822C-4042-8EDE-E8C02888254EQ35557004-E87C7A97-FC42-4F9F-B925-1E0808830485Q36276187-5CF18E49-C994-4E7E-ADFA-4A6370A71630Q36445557-E5037B5F-32F1-4FB2-B0AF-DDD0C60BAFE1Q36463004-9BC8EA09-441F-4166-8B75-90D96033C102Q36649681-F75F534E-66A0-4D81-9ACC-823C243B9EC0Q37089746-F1050C5E-2E8D-489C-A6A0-F97CD2A7B3A9Q37262766-709A05F4-3ACF-4D6A-B37F-CBA2CF88F90AQ37300008-3578DCBF-8790-4A25-AD33-27EE3245AF5CQ37310677-EBB7D7F5-7B37-423A-AFD2-F2C324D6D718Q37330624-14B30718-EB57-4C3D-8B0D-F2956E36EAE8Q37399961-0E12DA38-E4A3-416A-AD07-74800512A381Q37582126-30893C13-B6B5-460B-B001-0446B1389837Q37718852-70499BB5-52B2-40FF-81D7-680278621F2AQ37845399-B55F94BF-ABBB-48A5-9BF9-4AB3CD18C4E6Q37859842-359A2804-E867-4A6A-AADE-E6E4DB31B24AQ37926486-1C336E1B-28B0-4664-BD6F-E1CE1C0E19E1Q37984486-9DDC8238-2C0E-40E1-AB8E-45C39159CE15Q37989391-5E798407-E20D-477A-A190-D222D7EC37EAQ38081027-F2BE3A15-A323-483B-92F4-32955DE7E14CQ38614156-E1FF1C86-30FC-4039-977F-825442C57731Q38637597-2E40D337-A0E3-4210-A8DE-D580958A0D91Q38924562-73D037DC-B7EB-419F-8FCB-8E3C82204EBDQ38950257-60D9B5A1-D265-4904-9CE4-0638F7AEDE51Q38957410-48881083-23CF-4562-8A46-793448BEE63B
P2860
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.
@en
type
label
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.
@en
prefLabel
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.
@en
P2093
P1433
P1476
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery
@en
P2093
David Onion
Kriss Aslan
Leonard W Seymour
Mark Lyons
Miriam Bazan-Peregrino
Nicky K Green
Ratna Rajaratnam
Sarah Hale
Sue Phipps
Vivien Mautner
P304
P356
10.1016/J.YMTHE.2006.01.003
P577
2006-03-31T00:00:00Z